Peptide ReadinessDiscuss your requirements
Back to database

FDA APPROVED COMPARATOR

Enlicitide decanoate

An oral peptide adoption precedent with relevance to lipid pathways and future primary care implementation models.

Conceptual three-dimensional molecular signature for Enlicitide decanoate; not an exact chemical structure.
Oral macrocyclic PCSK9 inhibitor peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 10 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved as Lipfendra on 15 July 2026 to reduce low density lipoprotein cholesterol

MHRA / UK LICENCE

UK status is not established in this record; no UK approval is inferred from the FDA action

NICE STATUS

No NICE recommendation identified in this record

NHS ACCESS

No NHS access is inferred from the FDA approval

PRIVATE LAWFUL USE CONTEXT

US approval does not create a UK licence or routine UK availability

EVIDENCE MATURITY

FDA authorised evidence for a defined lipid lowering indication

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Emerging cardiometabolic market

PROFESSIONAL RELEVANCE

Track any future UK authorisation, NICE activity, pathway positioning and adoption requirements while keeping US and UK status distinct.

Product, formulation and indication

Lipfendra

US · Tablet

Reduction of low density lipoprotein cholesterol

Status history

Lipfendra approval of 15 July 2026 added as a new FDA authorised comparator.

FDA approved oral peptide comparator

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.